{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000050","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.777903+00:00","generated_at":"2026-06-02T05:41:42.404852+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia Q1 net loss narrows to $18M; Vafseo FDA approved, launch set for Jan 2025","bullets":["Total revenues $32.6M (Q1 2024) vs $40.0M (Q1 2023); Auryxia net product revenues $31.0M vs $34.7M.","Net loss of $18.0M improved from $26.9M loss in prior year; R&D spend reduced to $9.7M from $19.7M.","Vafseo (vadadustat) FDA approved Mar 27 for dialysis anemia; launch activities underway, availability Jan 2025.","Drew $7.5M second tranche from BlackRock debt facility; $10M remaining borrowing capacity through Dec 31, 2024.","Amended Vifor license agreement: repayment of working capital fund via tiered royalties on Vafseo sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000050","json":"https://secwatch.observer/filing/0001517022-24-000050.json","markdown":"https://secwatch.observer/filing/0001517022-24-000050.md","text":"https://secwatch.observer/filing/0001517022-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000050/0001517022-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000050/akba-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:41:42.404852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e45e1c053649146b6b1ffeed1d832e8747909604","claim":"Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $32.6 million, net income Net loss was $18.0 million. Guidance reaffirmed.","evidence_excerpt":"Total revenues were $32.6 million for the first quarter of 2024 compared to $40.0 million for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000050/0001517022-24-000050-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$32.6 million"},{"label":"Net income","value":"Net loss was $18.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}